Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

Dacomitinib, an irreversible pan-HER inhibitor, had shown modest clinical activity in squamous cell carcinoma of head and neck (SCCHN) patients. Therefore, validated predictive biomarkers are required to identify patients most likely to benefit from this therapeutic option. To characterize the genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kie Kyon, Jang, Kang Won, Kim, Sangwoo, Kim, Han Sang, Kim, Sung-Moo, Kwon, Hyeong Ju, Kim, Hye Ryun, Yun, Hwan Jung, Ahn, Myung Ju, Park, Keon Uk, Ramnarayanan, Kalpana, McPherson, John R., Zhang, Shenli, Rhee, Je-Keun, Vettore, André L., Das, Kakoli, Ishimoto, Takatsugu, Kim, Joo Hang, Koh, Yoon Woo, Kim, Se Hun, Choi, Eun Chang, Teh, Bin Tean, Rozen, Steven G., Kim, Tae-Min, Tan, Patrick, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726344/
https://www.ncbi.nlm.nih.gov/pubmed/26790612
http://dx.doi.org/10.1038/srep19552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726344/
https://www.ncbi.nlm.nih.gov/pubmed/26790612
http://dx.doi.org/10.1038/srep19552

Ejemplares similares